Skip to main content
Skip main navigationClose Drawer MenuOpen Drawer Menu

ADVANCE praiseFree Access

Letters to the editor

J Am Coll Cardiol, 45 (3) 469


Sometimes an artfully crafted quasi-acronym can help distinguish one otherwise indistinguishable clinical advance from another (1–3). The infectiousness of this engaging wOrdPlay is evidenced by a recent report describing the role of Tirofiban for prevention of iscHEmIc complicatioNS among high-risk pAtieNts undergoIng coronary angioplasTY (4)—a distinguished advance indeed!

  • 1. The ADVANCE Investigators : "Rationale and design of the ADVANCE study: a randomized trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus: Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation". J Hypertens Suppl 2001; 19 Suppl 4: S21.

    Google Scholar
  • 2. Serruys P.W., Foley D.P., Suttorp al. : "A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study". J Am Coll Cardiol 2002; 39: 393.

    View ArticleGoogle Scholar
  • 3. Russell S.D., Selaru P., Pyne al. : "Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial". Am Heart J 2003; 145: 179.

    CrossrefMedlineGoogle Scholar
  • 4. Valgimigli M., Percoco G.F., Barbieri al. : "The additive value of tirofiban administered with the high dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty (ADVANCE) trial". J Am Coll Cardiol 2004; 44: 14.

    View ArticleGoogle Scholar